Orange Book drug · Generic (ANDA)

Fenofibrate (micronized)

Fenofibrate

ANDA 210705 3 strengths Ajanta Pharma Ltd

Approved

Sep 10, 2018

Strengths

Listed patents

Applications

What does the FDA Orange Book show for Fenofibrate (micronized)?

Fenofibrate (micronized) contains Fenofibrate and appears in 17 FDA Orange Book applications. ANDA 210705 is the lead filing, with 3 presentations shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.

FDA applications: 17; lead ANDA 210705
Lead application holder: Ajanta Pharma Ltd
Product presentations: 3
Marketing categories: Prescription
Reference roles: RS
TE codes: AB
Listed patents: 0
Exclusivity records: 0

Sourced from the official FDA Orange Book data file · snapshot refreshed Jul 02, 2026, 06:34 PM

FDA product-presentation matrix

Every product number in this exact application

Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
Product	Strength	Dosage form / route	Marketing status	TE code	Reference role
001	67MG	CAPSULEORAL	Prescription	AB	None posted
002	134MG	CAPSULEORAL	Prescription	AB	None posted
003	200MG	CAPSULEORAL	Prescription	AB	RS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Ajanta Pharma Ltd

The Orange Book identifies this organization as the applicant responsible for ANDA 210705.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not

FDA marketing status

3 presentations listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

TE code AB across rated presentations

An AB code is an A-rating: FDA considers the product therapeutically equivalent to pharmaceutical equivalents in the same Orange Book heading and equivalence group.

Patent & exclusivity record

No listed patents or exclusivity records

This means none appear for this application in the current Orange Book files. It is not a freedom-to-operate opinion and does not rule out unlisted patents, regulatory barriers, or product-specific rights.

Same-ingredient landscape

31 other ANDAs and 7 other NDAs found

26 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

ANDA 210705 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Capsule · Oral

Fenofibrate

20 applications

Product rows: 59
Active applications: 13
Active with AB row: 12

Antara (micronized) · NDA 021695 Lipofen · NDA 021612 Lipidil · NDA 019304

Why are clinical sections unavailable?

Exact application-label matching status

Exact source match queuedQueue ANDA-210705

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

3 approved presentations · ANDA 210705

TE AB

Strength: 67MG
Dosage form: CAPSULE
Route: ORAL
Marketing status: Prescription

Key dates

Approval, patents, exclusivity

Approval
FDA approval date of this drug product.
Sep 10, 2018
8 yr ago
Today

Pharmaceutical detail

FDA product record

Active ingredient

FENOFIBRATE

Strength

67MG

Dosage form

CAPSULE

Route

ORAL

TE code

Application

ANDA 210705

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Reference standard (RS)

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Other FDA applications for Fenofibrate (micronized)

16 additional filings · 16 generic

The FDA has approved 17 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.

Other FDA applications approved under the product name Fenofibrate (micronized), with applicant, approval date, number of strengths, therapeutic-equivalence code, and marketing status.
Application	Applicant	Approved	Strengths	TE code	Status
ANDA 075753	Rhodes Pharms	Sep 03, 2002	3	AB	Prescription
ANDA 075868	Impax Labs	Oct 27, 2003	3	—	Discontinued
ANDA 090859	Chartwell Rx	Mar 01, 2012	2	AB	Prescription
ANDA 201748	Sun Pharm Inds Ltd	Oct 31, 2014	2	—	Discontinued
ANDA 202252	Apotex	Jul 26, 2013	2	AB	Prescription
ANDA 202579	Pharmobedient	Jan 10, 2013	2	—	Discontinued
ANDA 202676	Rising	Oct 23, 2012	3	—	Discontinued
ANDA 205566	Glenmark Pharms Ltd	Apr 07, 2017	3	AB	Prescription
ANDA 207378	Invagen Pharms	Mar 28, 2017	3	—	Discontinued
ANDA 207564	Ingenus Pharms LLC	Apr 19, 2019	3	—	Discontinued
ANDA 207805	Reyoung	Nov 16, 2017	3	AB	Prescription
ANDA 209504	Ani Pharms	Apr 30, 2018	3	AB	Prescription
ANDA 210782	Torrent	Jun 26, 2018	3	AB	Prescription
ANDA 211407	Chartwell	Jan 31, 2024	3	AB	Prescription
ANDA 212232	Aurobindo Pharma Ltd	Sep 20, 2021	3	AB	Prescription
ANDA 213842	Alembic	Oct 19, 2020	3	AB	Prescription

Active-ingredient family

Brand + generics

Generic (ANDA) of Fenofibrate

View full Fenofibrate family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.